Company intelligence / Profile preview

Akorion

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Akorion was an early-stage biotechnology company focused on developing precision medicines for kidney diseases by targeting podocyte biology. Founded by Dr. Peter Mundel and backed by Third Rock Ventures, the company specialized in the regulation of the actin cytoskeleton and its role in maintaining the kidney's filtration barrier. Akorion's research led to the identification of TRPC5 as a critical therapeutic target for proteinuric kidney diseases like FSGS. The company's assets and scientific team were eventually integrated into Goldfinch Bio, which advanced the pipeline into clinical trials. Following the dissolution of Goldfinch Bio in 2023, the lead programs originated at Akorion were acquired by Ironwood Pharmaceuticals.

Therapeutic areas: Nephrology
Modalities: Small moleculeMonoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on Akorion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Akorion.

Explore the full profile